Novavax (NVAX) revealed promising preliminary results from the SHIELD-Utah study, indicating that its 2024-2025 COVID-19 Vaccine, Adjuvanted and targeting the JN.1 strain, demonstrates fewer and less severe reactogenicity symptoms compared to the Pfizer (PFE) and BioNTech (BNTX, Financial) mRNA vaccine for the same period.
Conducted as a real-world study, findings were shared at the Congress of the European Society of Clinical Microbiology and Infectious Diseases 2025. The study highlights that healthcare workers vaccinated with Novavax reported significantly fewer adverse symptoms compared to their Pfizer-BioNTech counterparts. Specifically, Novavax recipients experienced an average of 1.7 symptoms, compared to 2.8 systemic symptoms reported by those receiving the Pfizer-BioNTech vaccine. Furthermore, 43.8% of individuals vaccinated with Pfizer-BioNTech's shot reported experiencing at least one symptom at Grade 2 or higher severity, while only 24.2% of Novavax recipients did so.
Additionally, local reactogenicity events were recorded at a 12.5% lower rate in Novavax recipients. The study also evaluated the vaccines' impacts on daily routines, revealing that recipients of the Novavax vaccine experienced fewer disruptions to activities, including work and family duties, than those vaccinated with Pfizer-BioNTech's offering.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 20 analysts, the average target price for BioNTech SE (BNTX, Financial) is $135.85 with a high estimate of $170.77 and a low estimate of $105.51. The average target implies an upside of 32.74% from the current price of $102.34. More detailed estimate data can be found on the BioNTech SE (BNTX) Forecast page.
Based on the consensus recommendation from 21 brokerage firms, BioNTech SE's (BNTX, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for BioNTech SE (BNTX, Financial) in one year is $24.60, suggesting a downside of 75.96% from the current price of $102.34. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the BioNTech SE (BNTX) Summary page.
